Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection
| Autor: | Laura Porretti, Paola Marchisio, Nicola Principi, Susanna Esposito, Elisabetta Prada, Rita Carsetti, Valentina Ierardi, Cristina Daleno, Annalisa Bosco, Alessia Scala |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Cell Extracts
Male Influenza vaccine Antibodies Viral Immune system Adjuvants Immunologic Antigen Recurrence OM-85 BV Influenza Human Humans Medicine Single-Blind Method Prospective Studies Seroconversion Adverse effect Respiratory Tract Infections Children B-Lymphocytes Immunity Cellular Bacterial lysate Influenza Recurrent respiratory tract infection General Veterinary General Immunology and Microbiology business.industry Immunogenicity Public Health Environmental and Occupational Health Dendritic Cells Virology Immunity Humoral Infectious Diseases medicine.anatomical_structure Immunoglobulin M Vaccines Inactivated Tolerability Influenza Vaccines Child Preschool Immunoglobulin G Immunology Molecular Medicine Female business Immunologic Memory Respiratory tract |
| Zdroj: | Vaccine. 32:2546-2552 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2014.03.055 |
| Popis: | It is known that the immunogenicity and efficacy of conventional inactivated influenza vaccines (IIVs) are not completely satisfactory in children. The aim of this prospective, randomised, single-blind study was to compare the immune response to, and the effectiveness and safety of, an IIV (Fluarix, GlaxoSmithKline Biologicals, Rixensart, Belgium) administered to 68 children aged 36-59 months affected by recurrent respiratory tract infections (RRTIs) who were vaccinated with (n=33) or without (n=35) the mixed bacterial lysate OM-85 BV (Broncho-vaxom, Vifor Pharma, Geneva, Switzerland). OM-85 BV had no effect on seroconversion or seroprotection rates, geometric mean titres, or dendritic cells, which were not significantly different between the two groups. Moreover, OM-85 BV did not significantly increase the pool of the memory B cells that produce IgG and IgM antibodies against the influenza antigens. However, respiratory morbidity was significantly lower in the children treated with OM-85 BV (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect